TABLE 3.

Clinical and molecular data for all 25 patients

	Gender/Race or Ethnicity	Age at Study Enrollment (years)	Histologic Diagnosis	Molecular Abnormalities	Duration of Therapy (weeks)
1	F/Caucasian	11.9	Anaplastic astrocytoma	No PDGFRA or MET ampl	6
2	F/African-American	15.5	Not available	Not available	11
3	F/Caucasian	8	Glioblastoma	No PDGFRA or MET ampl	12
4	M/Caucasian	14.9	Not available	Not available	6
5	F/Caucasian	16.8	Glioblastoma	No PDGFRA or MET ampl	< 1
6	F/Caucasian	5	Not available	Not available	6
7	F/African-American	7.7	Anaplastic astrocytoma	No PDGFRA or MET ampl	5
8	F/Hispanic	5.9	Not available	Not available	2
9	M/Caucasian	21.3	Glioblastoma	MET ampl; no PDGFRA ampl	3
10	M/Caucasian	5.3	Glioblastoma	No PDGFRA or MET ampl	< 1
11	M/Caucasian	6.5	Not available	Not available	4
12	F/Hispanic	10.1	High-grade glioma	No PDGFRA or MET ampl	16
13	M/Caucasian	7.4	Not available	Not available	2
14	M/Caucasian	16.1	Glioblastoma	No PDGFRA or MET ampl	48
15	F/Hispanic	16.9	High-grade glioma	Not available	1
16	F/Caucasian	5.7	Not available	Not available	4
17	M/Caucasian	13.1	Glioblastoma	PDGFRA ampl; no MET ampl	8
18	F/Caucasian	7.1	Not available	Not available	4
19	M/African-American	19.1	High-grade glioma	No PDGFRA or MET ampl	4.5
20	F/Hispanic	13.1	Glioblastoma	No PDGFRA or MET ampl a	3
21	F/Caucasian	13.8	Anaplastic astrocytoma	No PDGFRA or MET ampl	16
22	F/Caucasian	13	Glioblastoma	PDGFRA and MET ampl	9
23	M/Hispanic	14.9	High-grade glioma	Focal PDGFRA ampl; no MET ampl	25
24	M/Caucasian	2.9	Glioblastoma	PDGFRA ampl; no MET ampl	8
25	F/Caucasian	9.3	Glioblastoma	No PDGFRA or MET ampl	4

Abbreviations: F, female; M, male; ampl, amplification

Eleven patients (patients 2–6, 8, 10, 11, 13, 16, and 18) had a radiological diagnosis of diffuse intrinsic pontine glioma

^aA PDGFRA non-synonymous mutation was only identified in one of 10 tumors tested (patient 20)